BAYN Stock Overview
Operates as a life science company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €24.67 |
| 52 Week High | €31.03 |
| 52 Week Low | €18.38 |
| Beta | 0.98 |
| 1 Month Change | 7.35% |
| 3 Month Change | 8.46% |
| 1 Year Change | -8.38% |
| 3 Year Change | -63.04% |
| 5 Year Change | -62.23% |
| Change since IPO | 81.14% |
Recent News & Updates
Recent updates
Bayer (ETR:BAYN) Has A Somewhat Strained Balance Sheet
Dec 28
Innovative Launches And Decisive Moves Set Stage For Remarkable Growth In Pharmaceuticals And Consumer Health
Pharmaceutical and agriculture innovations are key strategies for growth, offsetting generic competition and boosting future revenues.Benign Growth For Bayer Aktiengesellschaft (ETR:BAYN) Underpins Stock's 25% Plummet
Nov 21These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Sep 13Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now
Aug 09These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Jun 11Shareholder Returns
| BAYN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.0% | -0.1% | -0.8% |
| 1Y | -8.4% | -24.8% | 16.9% |
Return vs Industry: BAYN exceeded the German Pharmaceuticals industry which returned -24.8% over the past year.
Return vs Market: BAYN underperformed the German Market which returned 16.9% over the past year.
Price Volatility
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: BAYN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BAYN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 90,885 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAYN fundamental statistics | |
|---|---|
| Market cap | €24.24b |
| Earnings (TTM) | -€3.25b |
| Revenue (TTM) | €46.58b |
Is BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYN income statement (TTM) | |
|---|---|
| Revenue | €46.58b |
| Cost of Revenue | €20.36b |
| Gross Profit | €26.22b |
| Other Expenses | €29.47b |
| Earnings | -€3.25b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 06, 2025
| Earnings per share (EPS) | -3.31 |
| Gross Margin | 56.28% |
| Net Profit Margin | -6.98% |
| Debt/Equity Ratio | 120.9% |
How did BAYN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/28 06:20 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bayer Aktiengesellschaft is covered by 55 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Rafael Bonardell Trianes | Banco de Sabadell. S.A. |
| Emily Field | Barclays |